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Purpose: To prevent overtreatment, it is very important to diagnose the precise distribution and characteristics of all cancer lesions, 
including small daughter tumors. The purpose of this study was to evaluate the efficacy of T2-weighted magnetic resonance imaging 
(T2W), diffusion-weighted magnetic resonance imaging (DWI), magnetic resonance spectroscopy (1H-MRS), and prostate biopsy (PBx) 
in the detection of intraprostatic cancer distribution.
Methods: All patients underwent T2W, DWI, 1H-MRS, and PBx followed by radical prostatectomy (RP). Individual prostates were 
divided into 12 segmental regions, each of which was examined for the presence or absence of malignancy on the basis of T2W, DWI, 
1H-MRS, and PBx, respectively. These results were compared with the histopathological findings for RP specimens. 
Results: We included 54 consecutive patients with biopsy-proven prostate cancer (mean age, 62.7 years; median prostate-specific 
antigen level, 5.7 ng/mL) in this study. We could detect cancer in 247 of 540 evaluable lesions.  The area under the receiver operator 
characteristic curve analysis yielded a higher value for DWI (0.68) than for T2W (0.65), 1H-MRS (0.54), or PBx (0.56). In 180 cancerous 
regions of RP specimens with false-negative PBx results, T2W+DWI had the highest positive rate (53.3%) compared with that of each 
sequence alone, including T2W (45.6%), DWI (41.1%), and 1H-MRS (30.0%).
Conclusions: Multiparametric magnetic resonance imaging (T2W, 1H-MRS, DWI) enables the detection of prostate cancer 
distribution with reasonable sensitivity and speciﬁcity. T2W+DWI was particularly effective in detecting cancer distribution with false-
negative PBx results. 
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INTRODUCTION
Prostate cancer (PCa) is a major disease affecting men world-
wide, and the detection of malignancy at an early stage is es-
sential to treatment [1,2]. In Cancer of the Prostate Strategic 
Urologic Research Endeavor, the proportion of patients with 
low-risk disease has increased, and conversely, high-risk diag-
noses have decreased [3]. The current methods of PCa detec-




80–100 ms; slice thickness, 3.0 mm; gap, 0.3 mm; and matrix, 
260 ×256. DWI images of the prostate and seminal vesicle 
included the following parameters: TR, 3,300–5,000 ms; TE, 
74–76 ms; slice thickness, 4.0 mm; gap, 0.3–0.4 mm; and ma-
trix, 88×128. 
 The following sequence and imaging conditions were used: 
sequence =point-resolved spectroscopy based 3D PROSE 
(PROstate spectroscopy imaging exam); TR/TE =2,000/130 
ms; spectral width =1,250 Hz; data acquisition points =256; 
activation area =8.0 or 16.0 cm2; encode =8 ×8 or 16 ×16; 
and number of excitations=2. A body coil was used for radio 
frequency transmission, whereas the receiver coil was an 
endorectal coil (BPX-10; Nihon Medrad K.K., Tokyo, Japan) 
placed on the anterior surface of the rectum in close contact 
with the posterior aspect of the prostate. Spectral data cor-
recting the volume of interest (VOI) were manually set on the 
axial localization image to cover the entire outer gland. VOI 
thickness was 2.0 cm. Six planes of very selective suppression 
radio frequency pulses were set at a region adjacent to a VOI. 
Full width at half maximum of water peak after shimming was 
less than 14 Hz in all participants. The 1H-MRS data were pro-
cessed by using the software supplied (SAGE II, General Elec-
tric Medical Systems) on the MRI console. Each spectral signal 
was zero-ﬁlled to 512 points and multiplied by 2 Hz of expo-
nential function. Fourier transformation, phase adjustment, 
frequency adjustment, baseline correction, and calculation of 
the CCr ratio (choline+creatine/citrate ratio) were carried out 
automatically. The peak areas of citrate (at 2.8 ppm), choline 
(at 3.2 ppm), and creatine (at 3.0 ppm) were measured. A CCr 
ratio ≥1.07 indicated the existence of cancer, as we reported 
previously [14]. On the basis of data from the 20 patients with 
localized PCa who underwent RP, we decided that the cutoff 
value for PCa diagnosis by 1H-MRS would be ≥1.07, which is 
equivalent to the mean+2 standard deviations of the CCr ratio 
for a normal (noncancerous) Pz at Teikyo University, Tokyo, 
Japan [14]. 
 MRI data sets were prospectively evaluated by a radiologist 
(TK, with 28 years’ accumulated experience in prostate MRI) 
and two urologists (K.K. and S.M., with 10 and 22 years’ accu-
mulated experience in prostate MRI, respectively). MRI data 
sets were assessed in consensus and reviewers were aware 
that patients had biopsy-proven PCa, but they were blinded to 
the initial PSA values and PBx results as well as to histopatho-
logic ﬁndings. MR images were evaluated; the criterion for 
cancer presence was a mass or nodule with homogenously low 
signal intensity showing ill-defined margins on T2W (Fig. 1B) 
[16] and appearing hyper-intense on DWI (Fig. 1C) [5,7,17]. 
1H-MRS images were evaluated; the criterion for cancer pres-
tion include digital rectal examination, serum concentration of 
prostate-specific antigen (PSA), and transrectal ultrasonogra-
phy-guided prostate biopsy (PBx), but these are of limited ac-
curacy for the majority of early cancers. To prevent overtreat-
ment [4], the most important goal is to diagnose the precise 
distribution and characteristics of all cancer lesions, including 
small daughter tumors. As a noninvasive tool, magnetic reso-
nance imaging (MRI) plays an increasingly important role in 
the detection, localization, and staging of PCa [5-8]. Although 
T2-weighted magnetic resonance imaging (T2W) has been the 
mainstay of prostate MRI, it is generally acknowledged to be 
nonspeciﬁc for cancer, because low-signal-intensity lesions in 
the peripheral zone (Pz) can result from prostatitis, scarring, 
or hyperplasia [9]. Diffusion-weighted MRI (DWI) can offer 
valuable information about the microstructure and patho-
physiology of tissues based on the diffusion properties of the 
water molecules [8,10-13]. MR spectroscopy (1H-MRS) has the 
ability to provide chemical information about metabolites in 
normal and abnormal tissues. The purpose of this study was 
to evaluate the efficacy of T2W, DWI, 1H-MRS, and PBx in the 
detection of intraprostatic cancer distribution.
MATERIALS AND METHODS
1. Patients
Between February 2009 and July 2013, patients with cT1c-
T2N0M0 biopsy-proven localized PCa who underwent T2W, 
DWI, 1H-MRS, and PBx followed by radical prostatectomy 
(RP), and who did not receive neoadjuvant hormonal therapy, 
were included in this study. Patients with a PSA value above 
2.5 ng/mL underwent T2W and DWI, followed by PBx. We 
previously demonstrated that MRS had no effect on PBx [14]. 
Therefore, we performed 1H-MRS after PBx, followed by RP. 
Full data included age; preoperative PSA values; MRI data in-
cluding T2W, DWI, and 1H-MRS; and PBx pathological results. 
TNM classiﬁcation was based on guidelines set forth in the 
Union for International Cancer Control, 7th edition [15]. The 
present study was carried out in accordance with the protocol 
and in compliance with the moral, ethical, and scientiﬁc prin-
ciples governing clinical research as set forth in the Declara-
tion of Helsinki (1989).
2. MRI procedures 
All examinations were performed by using a 1.5-Tesla MRI 
system (Signa LX Horizon Echospeed, General Electric Medi-
cal Systems Inc., Buckinghamshire, UK). T2W images of the 
prostate and seminal vesicle included the following param-
eters: repetition time (TR), 3,300–4,000 ms; echo time (TE), 




4. Analysis of data set
For tumor localization, a prostate was divided into halves: 
right (R) and left (L). Then each half was divided into 6 seg-
ments: outside Pz anterior, outside Pz posterior, inside Pz, 
central Tz, Tz anterior, and apex. Thus, in each case, we had 12 
segmental regions of interest (ROIs) within the whole prostate 
of each patient (Fig. 2). PBx specimens for each segmental 
region were evaluated for cancer presence. To evaluate the di-
agnostic performance of each MR sequence (Fig. 2), the sensi-
tivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of T2W, DWI, 1H-MRS, and PBx were 
compared between groups by using the Z-test. For this ap-
proach, the sensitivity of an imaging modality or PBx result 
was deﬁned as the probability of correctly identifying a histo-
pathologically proven cancer focus. Speciﬁcity was deﬁned 
as the probability of correctly identifying regions negative for 
cancer. In addition, we evaluated the combined diagnostic ac-
curacy of multiple imaging variables. We calculated areas un-
der the receiver operator curves (AUCs) of each MR sequence 
and PBx. An region of Interest study was performed by using 
Discover JMP ver. 11.0 (SAS Institute Inc., Cary, NC, USA). 
Variables are expressed as medians with interquartile ranges 
(IQRs). All P-values corresponded to two-sided tests, with a P-
value of 0.05 considered to represent a significant difference.
RESULTS
1. Patients and pathological data
In this study, 54 consecutive patients who underwent RP for 
PCa were evaluated. The characteristics of the patients are 
shown in Table 1. The mean age of the patients was 62.7 years, 
and the patients’ median initial PSA level was 5.7 ng/mL (IQR, 
4.4–7.6 ng/mL). The median intervals between T2W with DWI 
and PBx, PBx and 1H-MRS, and 1H-MRS and RP were 15.5, 
75.0, and 71.0 days, respectively. Tumor staging was as follows: 
33.3% were cT1c (n=18) and 66.7% were cT2  (n=36). Further-
ence was indicated regions in which the CCr ratio was ≥1.07 
as mentioned above (Fig. 1D) [14].
3. Histopathological analysis
PBx was performed as transrectal and transperineal biopsy 
under ultrasound guidance. Transrectal biopsy included 10 re-
gions of the Pz and transitional zone (Tz) of the middle gland. 
Transperineal biopsy included 2 regions of the apex gland. RP 
specimens were sliced into 5 mm-thick horizontal sections 
perpendicular to the dorsal surface of the urethral mucosa. 
The strip preparations were fixed in formalin and stained with 
hematoxylin-eosin. The pathological diagnoses were made 
by a single pathologist (K.H.). Sections were assessed for the 
presence of tumor and the Gleason score of individual foci of 
PCa. The grids used for mapping were similar to those used for 
MRI evaluation to allow for correlation of radiologic ﬁndings 
and pathologic ﬁndings.
Fig. 1. Prostate cancer (PCa) in a 68-year-old man with an initial 
prostate-specific antigen value of 14 ng/mL. (A) Radical prosta-
tectomy (RP) specimen: histopathologic findings at the periph-
eral zone at the midprostate level indicate tumor presence (Glea-
son score, 4+3); the diagonal red lines indicate the presence of 
PCa on the basis of histopathological findings. The remaining 
panels (B–D) correspond to the slices of the RP specimen. (B) Axi-
al T2-weighted magnetic resonance imaging (T2W) image dem-
onstrating a mass of homogeneously low signal intensity with ill-
defined margins (red arrow). (C) Diffusion-weighted magnetic 
resonance imaging image demonstrates a mass of hyper-signal 
intensity (red arrow). (D) Magnetic resonance spectroscopy im-
aging shows abnormal metabolism characterized by high cho-
line and low citrate peaks in the region of the T2W abnormality 
(red area). Red dotted-line boxes indicate the regions suggestive 
of malignancy. Blue dotted-line boxes indicate the normal find-





Fig. 2. Each prostate was divided into 12 segmented regions. For 
tumor localization, each prostate was divided into halves: right 
and left. Each half was further divided into 6 regions as follows: (A) 
outside peripheral zone (Pz) anterior, (B) outside Pz posterior, (C) 
inside Pz, (D) central transitional zone (Tz), (E) Tz anterior, (F) apex. 




more, tumors in 43 patients (79.6%) were staged as pT2N0M0, 
whereas those in 11 patients (20.4%) were staged as pT3N0M0 
at the pathologic analysis. No regional lymph node involve-
ment or distant metastases were detected in any of the patients. 
RP specimens showed 17 patients (31.5%) with GS 3+3, 11 pa-
tients (20.4%) with GS 3+4, 17 patients (31.5%) with GS 4+3, 8 
patients (14.8%) with GS 4+4, and 1 patient (1.8%) with GS 4+5. 
In addition, 23 patients (42.6%) had a positive surgical margin. 
 Of the total number of 540 ROIs, cancer was detected in 
174 regions (32.2%) in T2W, in 130 regions (24.1%) in DWI, in 
133 regions (24.6%) in 1H-MRS, in 109 regions (20.2%) in PBx, 
and in 247 regions (45.7%) in RP specimens.
2. Comparison with each MR sequence alone
The power of cancer detection by each sequence was investi-
gated by comparing the sensitivity, specificity, PPV, and NPV 
(Fig. 3A). PBx had the lowest sensitivity (27.1%). That is, PBx 
had a high false-negative rate. Sensitivity for T2W was higher 
than it was for DWI or 1H-MRS, and speciﬁcity for T2W was 
lower than it was for DWI or 1H-MRS for all regions. DWI had 
the highest specificity (92.8%), PPV (83.8%), and NPV (66.3%) 
in each sequence alone. AUC analysis showed that DWI had a 
higher AUC (0.68) than did T2W (0.65), 1H-MRS (0.54), or PBx 
Table 1. Characteristics of the patients (n=54)
Characteristic Value
Age (yr), mean±SD 62.7±6.4
Baseline PSA (ng/mL) 5.7 (4.4–7.6)
Interval between T2W with DWI and PBx (day) 15.5 (24.8–54.5)
Interval between PBx and 1H-MRS (day) 75.0 (39.0–107.0)
Interval between 1H-MRS and prostatectomy (day) 71.0 (34.5–114.3)
cT 
   cT1c 18 (33.3)
   cT2 36 (66.7)
pT 
   pT2a 17 (31.5)
   pT2b 2 (3.7)
   pT2c 24 (44.4)
   pT3a 7 (13.0)
   pT3b 4 (7.4)
Gleason score 
   3+3 17 (31.5)
   3+4 11 (20.4)
   4+3 17 (31.5)
   ≥4+4 9 (16.6)
Values are presented as median (interquartile range) or number (%) 
unless otherwise indicated.
SD, standard deviation; PSA, prostate-specific antigen; T2W, T2-weight-
ed magnetic resonance imaging; DWI, diffusion-weighted magnetic 
resonance imaging; PBx, prostate biopsy; 1H-MRS, magnetic resonance 
spectroscopy.
Sensitivity Specificity PPV NPV AUC
T2W 0.48 0.81 0.68 0.65 0.65
DWI 0.44 0.93 0.84 0.66 0.68
1H-MRS 0.29 0.86 0.62 0.58 0.54
PBx 0.27 0.86 0.62 0.58 0.56
T2W+DWI 0.56 0.79 0.69 0.68 0.68
T2W+1H-MRS 0.62 0.65 0.60 0.67 0.63
T2W+DWI+1H-MRS 0.68 0.63 0.61 0.70 0.66
Sensitivity Specificity PPV NPV AUC
T2W 0.60 0.67 0.68 0.59 0.64
DWI 0.51 0.89 0.84 0.61 0.70
1H-MRS 0.33 0.72 0.58 0.48 0.53























Fig. 3. Diagnostic accuracy. (A) The diagnostic accuracy of each sequence alone and multiparametric magnetic resonance imaging 
(MRI) in all segmental regions. (B) The diagnostic accuracy only in segmental regions of peripheral zone (Pz). PPV, positive predictive 
value; NPV, negative predictive value; AUC, areas under the receiver operator curve; T2W, T2-weighted MRI; DWI, diffusion-weighted 
magnetic resonance imaging; 1H-MRS, magnetic resonance spectroscopy; PBx, prostate biopsy.




(0.56) (Fig. 3A). The results of the ROC analysis for T2W, DWI, 
1H-MRS, and PBx are shown in Fig. 4. In the ROC analysis, 
DWI had the best accuracy for detecting the cancer distribu-
tion in each sequence alone. Of 247 cancerous regions in RP 
specimens, 180 could not be diagnosed by PBx. In 180 cancer-
ous regions of RP specimens with negative PBx results, we 
compared the positive rates of each sequence alone. T2W had 
the highest positive rate (45.6%) compared with DWI (41.1%) 
and 1H-MRS (30.0%) (Fig. 5).
 Fig. 3B shows the diagnostic accuracy only in segmental 
regions of the Pz. Sensitivity was higher in segmental regions 
of the Pz, regardless of MRI modality or PBx, than in other 
segmental regions, whereas specificity and NPV were lower. 
As was the case in all segmental regions, DWI had the highest 
AUC in each sequence alone.
1) Multiparametric MRI
The diagnostic accuracy of multiparametric MRI (by combining 
MRI modalities) is shown in Fig. 3A. We evaluated the results of 
T2W+DWI, T2W+1H-MRS, and T2W+DWI+1H-MRS, respec-
tively. Compared with MRI sequences alone, multiparametric 
MRI had higher sensitivity. That is, multiparametric MRI could 
decrease the false-negative rate. On the other hand, in view of 
the results that multi-parametric MRI could decrease speci-
ficity compared with each sequence alone, multi-parametric 
MRI was not effective in decreasing the false-positive rate. 
With the exclusion of 1H-MRS, there were no obvious differ-
ences in the AUC between T2W alone, DWI alone, and mul-
tiparametric MRI. In 180 cancerous regions of RP specimens 
with negative PBx results, T2W+DWI had the highest positive 
rate (53.3%) compared with each sequence alone (Fig. 5).
2) Malignant potential
Among all 540 regions in the RP specimens, we detected 247 
cancerous regions (45.7%). Their Gleason scores were as 
follows: 111 regions (44.9%) had a Gleason 3+3, 56 regions 
(22.7%) had a Gleason 3+4, 47 regions (19.0%) had a Gleason 
4+3, and 29 regions (11.7%) had a Gleason 4+4. The positive 
rate of each sequence alone by Gleason score is shown in Fig. 
6. The positive rate of Gleason 3+3 specimens was almost 30% 
in all modalities. There was little difference in the positive rate 
of any Gleason score. In contrast, MR modality tended to show 
an increase in the positive rate with increasing Gleason score. 
Notably, the positive rates of DWI (62.1%) and T2W (69.0%) in 
Gleason 4+4 regions were over 60%. 
DISCUSSION
It is well known that precise diagnosis faces real limitations 
with digital rectal examination, serum PSA, diagnostic imag-
ing, and PBx [18]. MRI has already been established as a non-
invasive diagnostic tool [19]. However, the ideal MRI sequence 
modality combination has yet to be established. 
 In our study, DWI had the highest specificity, PPV, NPV, and 
AUC to detect the presence or absence of PCa in intraprostatic 
segmental regions (Fig. 3A). We could obtain similar analytical 
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Fig. 4. Results of the region of Interest analysis for T2-weighted 
magnetic resonance imaging (T2W), diffusion-weighted mag-
netic resonance imaging (DWI), magnetic resonance spectros-
copy (1H-MRS), and prostate biopsy (PBx). Area under the receiv-
er operator characteristic curve (AUC) analysis found that DWI 
had a higher AUC of 0.68 compared with T2W (0.65), 1H-MRS 













Fig. 5. Of 247 cancerous regions in radical prostatectomy (RP) 
specimens, 180 could not be diagnosed by prostate biopsy 
(PBx). In 180 cancerous regions of RP specimens with negative 
PBx results, T2-weighted magnetic resonance imaging 
(T2W)+diffusion-weighted magnetic resonance imaging (DWI) 
had the highest positive rate (53.3%) compared with T2W alone 
(45.6%), DWI alone (41.1%), and magnetic resonance spectros-
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an important quantitative biophysical parameter that can be 
used to differentiate benign from malignant prostate tissue 
[20]. In the European Society of Urogenital Radiology (ESUR) 
prostate MR guidelines (2012) [5], DWI is noted to be a pow-
erful clinical tool, as it allows apparent diffusion coefficient 
(ADC) maps to be calculated, enabling qualitative and quan-
titative assessment of PCa aggressiveness. Even though we did 
not use an ADC map in this study, DWI had the best outcome 
among the MRI modalities.
 The ESUR prostate MR guidelines (2012) reported that T2W 
alone is sensitive but not specific for PCa and should be im-
proved by using two other functional techniques [5,21]. Turk-
bey et al. [9] reported that sensitivity for T2W was signiﬁcantly 
higher than it was for dynamic contrast-enhanced MRI or 1H-
MRS, and that speciﬁcity for T2W was lower than it was for 
dynamic contrast-enhanced MRI or 1H-MRS (P<0.001) for all 
regions. Our data also demonstrated that, although T2W alone 
had the best sensitivity (48.2%), T2W alone had the worst speci-
ficity (81.2%) in each sequence (Fig. 3A). As a result, T2W (0.65) 
had a lower AUC than did DWI (0.68) (Fig. 3A). Therefore, 
although it had insufficient diagnostic capacity, T2W was abso-
lutely imperative for detecting cancer distribution on its own.
 On the other hand, 1H-MRS and PBx had low accuracy in 
detecting PCa localization. 1H-MRS uses metabolic informa-
tion and makes biochemical quantitation at speciﬁc regions 
of the prostate possible in a noninvasive manner [22]. The 
ratio of the sum of the citrate and choline peaks to the citrate 
peak can differentiate PCa from normal parenchyma [5,14, 
23-25]. In this study, however, as in our previous report [22], 
1H-MRS alone and multi-parametric MRI using 1H-MRS had 
a relatively lower AUC. This was especially the case due to 
the obvious low sensitivity of 1H-MRS compared with T2W or 
DWI. 1H-MRS can provide valuable information about lesion 
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Fig. 6. The positive rate of each sequence alone by Gleason score. The positive rate of diffusion-weighted magnetic resonance imaging 
(DWI; A) and T2-weighted magnetic resonance imaging (T2W; B) increased with increasing Gleason score. In contrast, regardless of 

































 It was previously reported that the standard PBx is poor at 
sampling cancers, leading to the underdiagnosis of clinically 
significant disease [26]. Sampling accuracy tends to decrease 
progressively when the prostate increases in size, not only due to 
the larger volume itself, but also because of the more dispersed 
and thin distribution of the Pz tissue owing to Tz enlargement 
[27]. In this study, compared with each MRI sequence, PBx had 
relatively low sensitivity and specificity in detecting PCa local-
ization. In addition, compared with MRI, we believe the most 
critical problem is that PBx is an invasive procedure.
 Recently, the usefulness of multiparametric MRI has been 
widely reported. Most of these authors concluded that mul-
tiparametric MRI is the best imaging sequence for the de-
tection of PCa [17,28]. In our study, although T2W+DWI+1H-
MRS showed the best sensitivity, no multiparametric MRI 
could surpass the AUC value of DWI alone (Fig. 3A). On the 
other hand, as shown in Fig. 5, in 180 cancerous regions of RP 
specimens with negative PBx results, T2W+DWI had a higher 
positive rate (53.3%) than any sequence alone, including T2W 
(45.6%), DWI (41.1%), and 1H-MRS (30.0%) (Fig. 5). Previ-
ously, Kim et al. [27] concluded that adjunct use of DWI with 
T2W could increase performance compared with T2W alone. 
Therefore, judging from the results in this study and previous 
reports, T2W+DWI is the best combination to detect cancer 
distribution under the present circumstances, especially in 
cancerous regions with negative PBx results.
 There were several limitations to this study. First, dynamic 
contrast-enhanced MRI, which has shown promise in several 
investigations, was not evaluated in the current study. Ocak et 
al. [28] reported improvement in speciﬁcity by combining T2W 
with dynamic contrast-enhanced MRI. We intend to incor-
porate dynamic contrast-enhanced MRI in the next cohort of 
patients studied. Second, we could not completely avoid the 
deformation and shrinkage of RP specimens after fixation, or 
errors in the sectioning angle. Although the issue of misreg-
istration has been approached in various ways [9], it is very 
difficult to correlate imaging ﬁndings with histopathologic 
ﬁndings. 
 In conclusion, we could show the efficacy and limitations 
of multiparametric MRI, including the findings that anatomic 
(T2W) and functional (dynamic contrast-enhanced MRI and 
1H-MRS) modalities increase the performance of MRI in de-
tecting cancer distribution. 
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